Novalar - Specialty Pharmaceuticals - Press Release Archive

Press Releases Archive

Aug 12, 2008 - Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse™ a Local Anesthetic Reversal Agent

May 12, 2008 - Novalar™ Receives FDA Approval for OraVerse™

Dec 18, 2007 - Novalar™ Strengthens Senior Management Team with Key Appointments

Nov 1, 2007 - Novalar™ Raises $30 Million in Series D Financing

Aug 22, 2007 - Novalar™ Appoints Steven J. Semmelmayer to its Board of Directors

July 25, 2007 - Novalar™ announces exclusive license to develop and commercialize antibiotic fiber for root canal therapy.

June 19, 2007 - Novalar™ announces acceptance of OraVerse New Drug Application for filing by FDA.

May 30, 2007 - Novalar™ hires Vice President of Marketing to direct launch of anesthetic reversal agent OraVerse™.

March 20, 2007 - Novalar™ presents results from successful studies of anesthetic reversal agent at International Association of Dental Research Annual Meeting.

Nov 15, 2006 - Novalar’s™ Positive Phase 2 Pediatric Study Results Support Recent Pivotal Data in Adolescents and Adults.

Oct 3, 2006 - Novalar™ Announces Positive Phase 3 Results for Novel Dental Anesthesia Reversal Agent.

March 16, 2006 - Novalar™ Initiates Pivotal Phase 3 Studies for Novel Dental Anesthesia Reversal Agent.

March 11, 2005 - Novalar Pharmaceuticals™ Raises $27 Million in Series C Financing.